Eli Lilly and Company Stock Price, News & Analysis (NYSE:LLY)

$84.03 0.35 (0.42 %)
(As of 11/24/2017 06:32 AM ET)
Previous Close$83.68
Today's Range$83.58 - $84.17
52-Week Range$65.66 - $89.09
Volume817,624 shs
Average Volume2.62 million shs
Market Capitalization$92.14 billion
P/E Ratio20.46
Dividend Yield2.49%
Beta0.34

About Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:LLY
CUSIP53245710
Phone317-276-2000

Debt

Debt-to-Equity Ratio0.66%
Current Ratio1.38%
Quick Ratio1.03%

Price-To-Earnings

Trailing P/E Ratio20.46
Forward P/E Ratio19.96
P/E Growth1.85

Sales & Book Value

Annual Sales$21.22 billion
Price / Sales4.36
Cash Flow$4.76 per share
Price / Cash17.66
Book Value$13.59 per share
Price / Book6.18

Profitability

Trailing EPS$2.11
Net Income$2.74 billion
Net Margins9.90%
Return on Equity30.27%
Return on Assets10.82%

Miscellaneous

Employees41,975
Outstanding Shares1,101,090,000

Frequently Asked Questions for Eli Lilly and Company (NYSE:LLY)

What is Eli Lilly and Company's stock symbol?

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company announced a quarterly dividend on Monday, October 16th. Stockholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share on Friday, December 8th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.48%. The ex-dividend date of this dividend is Tuesday, November 14th. View Eli Lilly and Company's Dividend History.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) released its earnings results on Tuesday, October, 24th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $1.03 by $0.02. The firm earned $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and Company had a return on equity of 30.27% and a net margin of 9.90%. The firm's quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the firm posted $0.88 EPS. View Eli Lilly and Company's Earnings History.

When will Eli Lilly and Company make its next earnings announcement?

Eli Lilly and Company is scheduled to release their next quarterly earnings announcement on Wednesday, January, 31st 2018. View Earnings Estimates for Eli Lilly and Company.

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company issued an update on its FY17 earnings guidance on Tuesday, October, 24th. The company provided EPS guidance of $4.15-4.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.16. The company issued revenue guidance of $22.4-22.7 billion, compared to the consensus revenue estimate of $22.51 billion.

Where is Eli Lilly and Company's stock going? Where will Eli Lilly and Company's stock price be in 2017?

17 brokers have issued 12 month price objectives for Eli Lilly and Company's stock. Their predictions range from $73.00 to $105.00. On average, they expect Eli Lilly and Company's stock price to reach $91.60 in the next twelve months. View Analyst Ratings for Eli Lilly and Company.

What are Wall Street analysts saying about Eli Lilly and Company stock?

Here are some recent quotes from research analysts about Eli Lilly and Company stock:

  • 1. According to Zacks Investment Research, "Lilly’s third-quarter 2017 results were strong with the company beating estimates on both counts. Lilly also raised its sales and earnings outlook for the second time this year mainly backed by strong uptake trends of new products. Lilly is also exploring strategic alternatives for the Animal Health business, a prudent decision in our view. Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue. Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. However, key drug Alimta will continue to be impacted by competition. Meanwhile, the recent high-profile pipeline setbacks, competition from immuno-oncology agents, loss of exclusivity for many drugs, and weak performance of the Animal Health segment this year are an investor concern." (10/30/2017)
  • 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
  • 3. UBS AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)

Who are some of Eli Lilly and Company's key competitors?

Who are Eli Lilly and Company's key executives?

Eli Lilly and Company's management team includes the folowing people:

  • David A. Ricks, Chairman of the Board, President, Chief Executive Officer (Age 49)
  • Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services (Age 52)
  • Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories (Age 63)
  • Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer (Age 48)
  • Michael J. Harrington, Senior Vice President, General Counsel (Age 54)
  • Stephen F. Fry, Senior Vice President - Human Resources and Diversity (Age 51)
  • Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA (Age 50)
  • Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology (Age 52)
  • Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications (Age 58)
  • Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications

Who owns Eli Lilly and Company stock?

Eli Lilly and Company's stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (1.03%), Janus Henderson Group PLC (0.99%), Legal & General Group Plc (0.47%), Swiss National Bank (377,575.22%), Capital International Investors (0.37%) and Schwab Charles Investment Management Inc. (0.37%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Company.

Who sold Eli Lilly and Company stock? Who is selling Eli Lilly and Company stock?

Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Point72 Asset Management L.P., State of Tennessee Treasury Department, Capital Bank & Trust Co, Teacher Retirement System of Texas, Rothschild Asset Management Inc., Forsta AP Fonden and California State Teachers Retirement System. Company insiders that have sold Eli Lilly and Company company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Company.

Who bought Eli Lilly and Company stock? Who is buying Eli Lilly and Company stock?

Eli Lilly and Company's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Schwab Charles Investment Management Inc., Skandinaviska Enskilda Banken AB publ, American Century Companies Inc., Candriam Luxembourg S.C.A., Schroder Investment Management Group, Sector Gamma AS and Honeywell International Inc.. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Company.

How do I buy Eli Lilly and Company stock?

Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly and Company's stock price today?

One share of Eli Lilly and Company stock can currently be purchased for approximately $84.03.

How big of a company is Eli Lilly and Company?

Eli Lilly and Company has a market capitalization of $92.14 billion and generates $21.22 billion in revenue each year. The company earns $2.74 billion in net income (profit) each year or $2.11 on an earnings per share basis. Eli Lilly and Company employs 41,975 workers across the globe.

How can I contact Eli Lilly and Company?

Eli Lilly and Company's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]


MarketBeat Community Rating for Eli Lilly and Company (LLY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  723 (Vote Outperform)
Underperform Votes:  545 (Vote Underperform)
Total Votes:  1,268
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Eli Lilly and Company (NYSE:LLY)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.292.332.382.50
Ratings Breakdown: 3 Sell Rating(s)
9 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
8 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
7 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $89.37$89.17$87.92$90.17
Price Target Upside: 7.02% upside5.96% upside11.49% upside15.16% upside

Consensus Price Target History for Eli Lilly and Company (NYSE:LLY)

Price Target History for Eli Lilly and Company (NYSE:LLY)

Analysts' Ratings History for Eli Lilly and Company (NYSE:LLY)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$86.00 -> $90.00N/AView Rating Details
11/1/2017BMO Capital MarketsSet Price TargetSell$73.00N/AView Rating Details
10/26/2017Berenberg BankReiterated RatingBuy$98.00N/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$92.00 -> $93.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesReiterated RatingBuy$105.00N/AView Rating Details
10/13/2017Barclays PLCBoost Price TargetOverweight$90.00 -> $98.00N/AView Rating Details
10/10/2017Credit Suisse GroupDowngradeOutperform -> Neutral$84.23 -> $88.00N/AView Rating Details
10/5/2017Goldman Sachs Group IncReiterated RatingBuy$92.00 -> $95.00N/AView Rating Details
10/4/2017Cowen IncReiterated RatingBuy$95.00LowView Rating Details
9/11/2017Jefferies Group LLCReiterated RatingBuy$89.00 -> $89.00LowView Rating Details
7/26/2017Oppenheimer Holdings, Inc.DowngradeOutperform -> Market Perform$90.00 -> $90.00LowView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingBuy$90.00 -> $91.00LowView Rating Details
7/4/2017Citigroup Inc.Reiterated RatingBuy$100.00LowView Rating Details
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00MediumView Rating Details
4/27/2017ArgusDowngradeBuy -> Hold$64.18 -> $81.00LowView Rating Details
11/26/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
6/15/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
12/22/2015Bank of America CorporationReiterated RatingBuy$104.00 -> $108.00N/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Eli Lilly and Company (NYSE:LLY)

Earnings by Quarter for Eli Lilly and Company (NYSE:LLY)

Earnings History by Quarter for Eli Lilly and Company (NYSE LLY)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018$1.07N/AView Earnings Details
10/24/2017Q3 2017$1.03$1.05$5.52 billion$5.66 billionViewN/AView Earnings Details
7/25/2017Q2 2017$1.05$1.11$5.60 billion$5.82 billionViewN/AView Earnings Details
4/25/2017Q1 17$0.96$0.98$5.22 billion$5.23 billionViewN/AView Earnings Details
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.66$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.66$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eli Lilly and Company (NYSE:LLY)
2017 EPS Consensus Estimate: $4.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.98$0.98$0.98
Q2 20172$1.04$1.06$1.05
Q3 20173$1.01$1.06$1.04
Q4 20172$1.03$1.07$1.05
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Eli Lilly and Company (NYSE:LLY)

Next Dividend:12/8/2017
Annual Dividend:$2.08
Dividend Yield:2.48%
Dividend Growth:1.30% (3 Year Average)
Payout Ratio:98.58% (Trailing 12 Months of Earnings)
49.41% (Based on This Year's Estimates)
44.73% (Based on Next Year's Estimates)
Track Record:2 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Eli Lilly and Company (NYSE:LLY)

Dividend History by Quarter for Eli Lilly and Company (NYSE LLY)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/16/2017quarterly$0.522.42%11/14/201711/15/201712/8/2017
6/19/2017quarterly$0.522.51%8/11/20178/15/20179/8/2017
5/1/2017quarterly$0.522.55%5/11/20175/15/20176/9/2017
12/13/2016quarterly$0.523.03%2/13/20172/15/20173/10/2017
10/17/2016quarterly$0.512.59%11/10/201611/15/201612/9/2016
6/20/2016quarterly$0.512.81%8/11/20168/15/20169/9/2016
5/2/2016quarterly$0.512.68%5/11/20165/13/20166/10/2016
12/8/2015quarterly$0.512.43%2/10/20162/12/20163/10/2016
10/19/2015quarterly$0.502.57%11/10/201511/13/201512/10/2015
6/15/2015quarterly$0.502.42%8/12/20158/14/20159/10/2015
5/4/2015quarterly$0.502.78%5/14/20155/18/20156/10/2015
12/15/2014quarterly$0.502.89%2/11/20152/13/20153/10/2015
10/20/2014quarterly$0.493.03%11/12/201411/14/201412/10/2014
6/16/2014quarterly$0.493.31%8/13/20148/15/20149/10/2014
5/5/2014quarterly$0.493.35%5/13/20145/15/20146/10/2014
12/16/2013quarterly$0.493.98%2/12/20142/14/20143/10/2014
10/21/2013quarterly$0.493.91%11/13/201311/15/201312/10/2013
6/18/2013quarterly$0.493.82%8/13/20138/15/20139/10/2013
5/6/2013quarterly$0.493.62%5/14/20135/16/20136/10/2013
12/17/2012quarterly$0.493.96%2/13/20132/15/20133/8/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Eli Lilly and Company (NYSE LLY)

Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 76.61%
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Insider Trades by Quarter for Eli Lilly and Company (NYSE LLY)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2017Alfonso G ZuluetaSVPSell2,003$83.67$167,591.01View SEC Filing  
10/4/2017Lilly Endowment IncMajor ShareholderSell205,000$86.81$17,796,050.00View SEC Filing  
9/29/2017Lilly Endowment IncMajor ShareholderSell195,000$85.14$16,602,300.00View SEC Filing  
9/15/2017Lilly Endowment IncMajor ShareholderSell190,000$82.53$15,680,700.00View SEC Filing  
8/31/2017Lilly Endowment IncMajor ShareholderSell180,000$81.06$14,590,800.00View SEC Filing  
7/31/2017Lilly Endowment IncMajor ShareholderSell220,000$83.09$18,279,800.00View SEC Filing  
6/22/2017Lilly Endowment IncMajor ShareholderSell210,000$84.43$17,730,300.00View SEC Filing  
6/20/2017Lilly Endowment IncMajor ShareholderSell215,000$83.05$17,855,750.00View SEC Filing  
6/12/2017Melissa S BarnesInsiderSell1,900$80.78$153,482.00View SEC Filing  
6/9/2017Michael J HarringtonVPSell22,833$79.97$1,825,955.01View SEC Filing  
5/4/2017Enrique A ConternoSVPSell25,000$82.76$2,069,000.00View SEC Filing  
3/30/2017Lilly Endowment IncMajor ShareholderSell210,000$84.67$17,780,700.00View SEC Filing  
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.00View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.68View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.39View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.00View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.30View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.76View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.39View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.20View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.08View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.84View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.00View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.00View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.00View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.10View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.78View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.74View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.40View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.00View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.00View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.83View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.00View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eli Lilly and Company (NYSE LLY)

Source:
DateHeadline
Analytics for Quant Score Drive Upgrade of Eli Lilly (LLY) to BuyAnalytics for Quant Score Drive Upgrade of Eli Lilly (LLY) to Buy
investorplace.com - November 24 at 12:09 PM
Analysts’ Recommendations for Merck in November 2017Analysts’ Recommendations for Merck in November 2017
finance.yahoo.com - November 24 at 9:45 AM
BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍ as of Nov 14BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍ as of Nov 14
www.reuters.com - November 23 at 6:10 AM
CrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Preclinical Type 2 Diabetes Research ProgramsCrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Preclinical Type 2 Diabetes Research Programs
globenewswire.com - November 22 at 2:05 AM
United Therapeutics PAH Drug's Exclusivity Period ExtendedUnited Therapeutics PAH Drug's Exclusivity Period Extended
finance.yahoo.com - November 22 at 2:05 AM
Morgan Stanley Raises Eli Lilly and Company (LLY) Price Target to $90.00Morgan Stanley Raises Eli Lilly and Company (LLY) Price Target to $90.00
www.americanbankingnews.com - November 21 at 5:40 PM
Celldex (CLDX) Initiates Phase II Study on Cancer CandidateCelldex (CLDX) Initiates Phase II Study on Cancer Candidate
finance.yahoo.com - November 20 at 4:21 PM
Lilly Confirms Date and Conference Call for 2018 Financial Guidance AnnouncementLilly Confirms Date and Conference Call for 2018 Financial Guidance Announcement
finance.yahoo.com - November 20 at 4:21 PM
Health nominee reaped big earnings from drug industry tenureHealth nominee reaped big earnings from drug industry tenure
marketbeat.com - November 20 at 11:33 AM
Eli Lilly and Company (LLY) Given Consensus Recommendation of "Hold" by AnalystsEli Lilly and Company (LLY) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 19 at 5:56 PM
Industry Group Rank Restrict Eli Lilly (LLY) Rating - Investorplace.comIndustry Group Rank Restrict Eli Lilly (LLY) Rating - Investorplace.com
investorplace.com - November 18 at 4:25 AM
Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference - PR Newswire (press release)Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference - PR Newswire (press release)
www.prnewswire.com - November 18 at 4:25 AM
Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive ConferenceLilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 18 at 4:25 AM
Head-To-Head Comparison: Eli Lilly and (LLY) versus Its PeersHead-To-Head Comparison: Eli Lilly and (LLY) versus Its Peers
www.americanbankingnews.com - November 17 at 3:32 PM
Industry Group Rank Restrict Eli Lilly (LLY) RatingIndustry Group Rank Restrict Eli Lilly (LLY) Rating
investorplace.com - November 17 at 3:20 PM
Eli Lilly and (LLY) vs. The Competition Financial ReviewEli Lilly and (LLY) vs. The Competition Financial Review
www.americanbankingnews.com - November 16 at 5:08 PM
[$$] Two Lawsuits Hit Express Scripts Unit on Pricing[$$] Two Lawsuits Hit Express Scripts Unit on Pricing
finance.yahoo.com - November 16 at 10:11 AM
Eli Lilly tripled the price of insulin under Trumps pick for HHS and Democrats are pouncing on thatEli Lilly tripled the price of insulin under Trump's pick for HHS and Democrats are pouncing on that
www.businessinsider.com - November 15 at 5:07 AM
Eli Lilly & Co. : LLY-US: Dividend Analysis : November 15th, 2017 (record date) : By the numbers : November 14, 2017Eli Lilly & Co. : LLY-US: Dividend Analysis : November 15th, 2017 (record date) : By the numbers : November 14, 2017
finance.yahoo.com - November 15 at 5:07 AM
Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech StocksDonald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks
finance.yahoo.com - November 15 at 5:07 AM
Lilly: Jardiance Reduces Risk Of Cardiovascular Death In Type 2 Diabetes And PADLilly: Jardiance Reduces Risk Of Cardiovascular Death In Type 2 Diabetes And PAD
www.rttnews.com - November 14 at 1:01 AM
Former Eli Lilly Executive Is Trump’s Choice for Health SecretaryFormer Eli Lilly Executive Is Trump’s Choice for Health Secretary
www.nytimes.com - November 14 at 1:01 AM
Trump nominates former drug company executive Alex Azar as next Health and Human Services secretaryTrump nominates former drug company executive Alex Azar as next Health and Human Services secretary
www.cnbc.com - November 13 at 8:00 PM
Eli Lilly & Co. (LLY) Names Philip Johnson to SVP and TreasurerEli Lilly & Co. (LLY) Names Philip Johnson to SVP and Treasurer
www.streetinsider.com - November 13 at 8:00 PM
Trump Taps Alex Azar, Former Drug Company Executive, for Health and Services SecretaryTrump Taps Alex Azar, Former Drug Company Executive, for Health and Services Secretary
www.nbcnews.com - November 13 at 8:00 PM
[$$] HHS Nominee Oversaw Big Drug Price Increases at Lilly[$$] HHS Nominee Oversaw Big Drug Price Increases at Lilly
finance.yahoo.com - November 13 at 8:00 PM
Cost of diabetes epidemic reaches $850 billion a yearCost of diabetes epidemic reaches $850 billion a year
finance.yahoo.com - November 13 at 8:00 PM
Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery diseaseJardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
finance.yahoo.com - November 13 at 8:00 PM
[$$] Oh, No, a Pharma Exec[$$] Oh, No, a Pharma Exec
finance.yahoo.com - November 13 at 8:00 PM
Insider Selling: Eli Lilly and Company (LLY) SVP Sells 2,003 Shares of StockInsider Selling: Eli Lilly and Company (LLY) SVP Sells 2,003 Shares of Stock
www.americanbankingnews.com - November 13 at 3:12 PM
Trump Taps Alex Azar, Former Drug Company Executive, for Health and Services Secretary - NBCNews.comTrump Taps Alex Azar, Former Drug Company Executive, for Health and Services Secretary - NBCNews.com
www.nbcnews.com - November 13 at 3:00 PM
Eli Lilly & Co. (LLY) Names Philip Johnson to SVP and Treasurer - StreetInsider.comEli Lilly & Co. (LLY) Names Philip Johnson to SVP and Treasurer - StreetInsider.com
www.streetinsider.com - November 13 at 3:00 PM
Trump Picks Former Eli Lilly Drug Executive as Health SecretaryTrump Picks Former Eli Lilly Drug Executive as Health Secretary
finance.yahoo.com - November 13 at 3:00 PM
Trump says hes nominating former Eli Lilly executive to head HHSTrump says he's nominating former Eli Lilly executive to head HHS
finance.yahoo.com - November 13 at 3:00 PM
Trump Today: President laughs as Duterte calls journalists ‘spies’Trump Today: President laughs as Duterte calls journalists ‘spies’
finance.yahoo.com - November 13 at 3:00 PM
President Trump Nominates Alex Azar for HHS SecretaryPresident Trump Nominates Alex Azar for HHS Secretary
finance.yahoo.com - November 13 at 3:00 PM
ETFs with exposure to Eli Lilly & Co. : November 13, 2017ETFs with exposure to Eli Lilly & Co. : November 13, 2017
finance.yahoo.com - November 13 at 3:00 PM
Lilly Appoints Philip Johnson to Senior Vice President and TreasurerLilly Appoints Philip Johnson to Senior Vice President and Treasurer
finance.yahoo.com - November 13 at 3:00 PM
New Data on FORTEO® (teriparatide  injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe OsteoporosisNew Data on FORTEO® (teriparatide injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis
finance.yahoo.com - November 11 at 5:02 PM
Elanco, Aratana Announce Positive Opinion on GALLIPRANT® (grapiprant tablets) in EuropeElanco, Aratana Announce Positive Opinion on GALLIPRANT® (grapiprant tablets) in Europe
finance.yahoo.com - November 11 at 5:02 PM
Eli Lilly (LLY) Industry Group Rank Limit RatingEli Lilly (LLY) Industry Group Rank Limit Rating
investorplace.com - November 10 at 11:26 AM
Zacks: Brokerages Expect Eli Lilly and Company (LLY) to Announce $1.08 Earnings Per ShareZacks: Brokerages Expect Eli Lilly and Company (LLY) to Announce $1.08 Earnings Per Share
www.americanbankingnews.com - November 10 at 5:20 AM
Pharma ETFs Down Post Q3 EarningsPharma ETFs Down Post Q3 Earnings
feeds.benzinga.com - November 9 at 1:36 PM
Trump Expected to Name Ex-Lilly Executive Azar HHS SecretaryTrump Expected to Name Ex-Lilly Executive Azar HHS Secretary
finance.yahoo.com - November 9 at 12:23 AM
Eli Lilly & Co. (LLY) Says Long-Term Use of Taltz Shows Efficacy Improvements in PsA at ACR/ARHPEli Lilly & Co. (LLY) Says Long-Term Use of Taltz Shows Efficacy Improvements in PsA at ACR/ARHP
www.streetinsider.com - November 8 at 7:21 PM
Read This Before Buying Eli Lilly and Company (LLY) For Its Upcoming $0.52 DividendRead This Before Buying Eli Lilly and Company (LLY) For Its Upcoming $0.52 Dividend
finance.yahoo.com - November 8 at 7:21 PM
Mesothelioma Market Spotlight 2017 - Eli Lilly is the leading company in terms of development - Research and Markets - Business Wire (press release)Mesothelioma Market Spotlight 2017 - Eli Lilly is the leading company in terms of development - Research and Markets - Business Wire (press release)
www.businesswire.com - November 8 at 2:18 PM
Eli Lilly & Co. (LLY) Says Long-Term Use of Taltz Shows Efficacy Improvements in PsA at ACR/ARHP - StreetInsider.comEli Lilly & Co. (LLY) Says Long-Term Use of Taltz Shows Efficacy Improvements in PsA at ACR/ARHP - StreetInsider.com
www.streetinsider.com - November 8 at 2:17 PM
ACR/ARHP 2017: Long-Term Use of Lillys Taltz® (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF InhibitorsACR/ARHP 2017: Long-Term Use of Lilly's Taltz® (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
finance.yahoo.com - November 8 at 2:17 PM
Ex-pharma exec Azar is top choice to run U.S. health agency -sourcesEx-pharma exec Azar is top choice to run U.S. health agency -sources
finance.yahoo.com - November 8 at 2:17 PM

Social Media

Financials

Chart

Eli Lilly and Company (NYSE LLY) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.